NICE to look again at Novartis' Xolair for Asthma
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, will again appraise Novartis' asthma drug Xolair (omalizumab), which could lead to widened recommendations. The institute has published a draft appraisal scope for the drug.